SG11202003754YA - High concentration protein formulations with reduced viscosity - Google Patents

High concentration protein formulations with reduced viscosity

Info

Publication number
SG11202003754YA
SG11202003754YA SG11202003754YA SG11202003754YA SG11202003754YA SG 11202003754Y A SG11202003754Y A SG 11202003754YA SG 11202003754Y A SG11202003754Y A SG 11202003754YA SG 11202003754Y A SG11202003754Y A SG 11202003754YA SG 11202003754Y A SG11202003754Y A SG 11202003754YA
Authority
SG
Singapore
Prior art keywords
high concentration
reduced viscosity
protein formulations
concentration protein
formulations
Prior art date
Application number
SG11202003754YA
Inventor
Bhami Shenoy
Original Assignee
Bhamis Research Laboratory Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bhamis Research Laboratory Pvt Ltd filed Critical Bhamis Research Laboratory Pvt Ltd
Publication of SG11202003754YA publication Critical patent/SG11202003754YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
SG11202003754YA 2017-05-16 2017-06-20 High concentration protein formulations with reduced viscosity SG11202003754YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201741017199 2017-05-16
PCT/IN2017/050250 WO2018211517A1 (en) 2017-05-16 2017-06-20 High concentration protein formulations with reduced viscosity

Publications (1)

Publication Number Publication Date
SG11202003754YA true SG11202003754YA (en) 2020-05-28

Family

ID=59388124

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202003754YA SG11202003754YA (en) 2017-05-16 2017-06-20 High concentration protein formulations with reduced viscosity

Country Status (5)

Country Link
US (3) US10646569B2 (en)
EP (1) EP3624846A1 (en)
CA (1) CA3063324A1 (en)
SG (1) SG11202003754YA (en)
WO (1) WO2018211517A1 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11357857B2 (en) 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
WO2015196091A1 (en) 2014-06-20 2015-12-23 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
US10646569B2 (en) 2017-05-16 2020-05-12 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
JP7345479B2 (en) * 2018-01-26 2023-09-15 ジェネンテック， インコーポレイテッド Composition and method of use
AU2019265005A1 (en) 2018-05-10 2020-12-17 Regeneron Pharmaceuticals, Inc. High concentration vegf receptor fusion protein containing formulations
US11153281B2 (en) 2018-12-06 2021-10-19 Bank Of America Corporation Deploying and utilizing a dynamic data stenciling system with a smart linking engine
JP2022523510A (en) 2019-01-31 2022-04-25 エレクトロフィ，インコーポレイテッド Particle formation and morphological structure
AU2020225202B2 (en) 2019-02-18 2023-10-26 Eli Lilly And Company Therapeutic antibody formulation
US11471512B2 (en) * 2019-03-01 2022-10-18 Merck Sharp & Dohme Llc Pharmaceutical compositions of a peptide
CN112137967B (en) * 2019-06-27 2023-01-24 鲁南制药集团股份有限公司 Recombinant human FGF21-Fc fusion protein freeze-dried preparation
CN114423431B (en) * 2019-08-14 2024-03-15 纳诺麦缇科斯有限责任公司(经营别称为Phd生物科学) Uracil skin pharmaceutical preparation
PE20221276A1 (en) * 2019-10-30 2022-09-05 Novartis Ag ANTIBODY FORMULATION CONTAINING CRIZANLIZUMAB
US20210188996A1 (en) * 2019-12-05 2021-06-24 Sanofi-Aventis U.S. Llc Formulations of anti-cd38 antibodies for subcutaneous administration
CA3187322A1 (en) * 2020-07-13 2022-01-20 Merck Patent Gmbh Viscosity reducing excipients and combinations thereof for highly concentrated protein formulations
EP4210757A2 (en) * 2020-09-11 2023-07-19 Comera Life Sciences, Inc. Excipient compounds for protein formulations
JP2023546503A (en) * 2020-10-26 2023-11-02 ヤンセン ファーマシューティカ エヌ．ベー． Safe administration of anti-tau antibodies
CN112342028B (en) * 2020-10-28 2021-07-09 中铁建华南建设(广州)高科技产业有限公司 Shield dispersing agent and preparation method and application thereof
IL303350A (en) 2020-12-04 2023-08-01 Macrogenics Inc Pharmaceutical compositions of a her2/neu antibody and use of the same
WO2022120014A1 (en) * 2020-12-04 2022-06-09 Macrogenics, Inc. Pharmaceutical compositions of a her2/neu antibody and use of the same
KR20230146515A (en) * 2020-12-10 2023-10-19 스템라인 테라퓨틱스, 인코포레이티드 Improved freeze-dried formulation
TW202308692A (en) * 2021-04-27 2023-03-01 俄羅斯聯邦商拜奧卡德聯合股份公司 Pharmaceutical composition of pembrolizumab and use thereof
WO2023011502A1 (en) * 2021-08-02 2023-02-09 甘李药业股份有限公司 Stable formulation comprising anti-il-4r antibody
WO2023040999A1 (en) * 2021-09-18 2023-03-23 江苏康宁杰瑞生物制药有限公司 Composition comprising pd-l1 antigen-binding fragment and use thereof
CN114279778A (en) * 2021-12-04 2022-04-05 南京岚煜生物科技有限公司 Preparation method of composite high-value reference product
TW202345902A (en) * 2022-04-14 2023-12-01 瑞士商百濟神州瑞士有限責任公司 Stable high concentration arginine formulations containing pd-1 antibody and methods of use thereof
CN114990049B (en) * 2022-04-26 2024-01-16 鼎康(武汉)生物医药有限公司 Method for simultaneously regulating glycoform and charge heterogeneity of cell expression product
WO2024023762A1 (en) * 2022-07-27 2024-02-01 Kashiv Biosciences, Llc A stable liquid composition of ocrelizumab

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3946732A (en) 1973-08-08 1976-03-30 Ampoules, Inc. Two-chamber mixing syringe
US4538920A (en) 1983-03-03 1985-09-03 Minnesota Mining And Manufacturing Company Static mixing device
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4648532A (en) 1986-05-09 1987-03-10 Green Russell D Mixing and discharge capsule
US4759749A (en) 1986-05-27 1988-07-26 Level 1 Technologies, Inc. Heater for physiological fluids
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US5730978A (en) 1989-09-01 1998-03-24 Fred Hutchinson Cancer Research Center Inhibition of lymphocyte adherence with α4β1-specific antibodies
US6033665A (en) 1989-09-27 2000-03-07 Elan Pharmaceuticals, Inc. Compositions and methods for modulating leukocyte adhesion to brain endothelial cells
DE4105781C1 (en) 1991-02-23 1992-01-02 Fresenius Ag, 6380 Bad Homburg, De
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
LU91067I2 (en) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab and its variants and immunochemical derivatives including immotoxins
DE4127675C2 (en) 1991-08-21 1996-08-14 Elbau Elektronik Bauelemente G Method and device for monitoring the flow of a fluid in a line, in particular for infusion systems
US5330426A (en) 1992-08-13 1994-07-19 Science Incorporated Mixing and delivery syringe assembly
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
ATE182625T1 (en) 1993-01-12 1999-08-15 Biogen Inc RECOMBINANT ANTI-VLA4 ANTIBODIES MOLECULES
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US5899880A (en) 1994-04-08 1999-05-04 Powderject Research Limited Needleless syringe using supersonic gas flow for particle delivery
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9610992D0 (en) 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
IN184589B (en) 1996-10-16 2000-09-09 Alza Corp
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
AR012894A1 (en) 1997-06-13 2000-11-22 Lilly Co Eli FORMULATION OF INSULIN IN STABLE SOLUTION, ITS USE TO PREPARE A MEDICINAL PRODUCT AND PROCESS FOR THE PREPARATION OF THE SAME.
US5994511A (en) 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
US6300308B1 (en) 1997-12-31 2001-10-09 Board Of Regents, The University Of Texas System Methods and compositions for inducing autoimmunity in the treatment of cancers
AU750414B2 (en) 1998-07-13 2002-07-18 Board Of Regents, The University Of Texas System Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids
US6406693B1 (en) 1998-07-13 2002-06-18 Board Of Regents, The University Of Texas System Cancer treatment methods using antibodies to aminophospholipids
US7919109B2 (en) 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US6443612B1 (en) 1999-12-02 2002-09-03 Wilhelm A. Keller Dynamic mixer
FR2804329B1 (en) 2000-02-02 2002-12-13 Poudres & Explosifs Ste Nale SYRINGE WITHOUT NEEDLE PROVIDED WITH A LID CONTAINING THE ACTIVE INGREDIENT
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
EP1324776B2 (en) 2000-10-12 2018-03-21 Genentech, Inc. Reduced-viscosity concentrated protein formulations
GB0100756D0 (en) 2001-01-11 2001-02-21 Powderject Res Ltd Needleless syringe
GB0113179D0 (en) 2001-05-31 2001-07-25 Novartis Ag Organic compounds
DE10133394A1 (en) 2001-07-13 2003-01-30 Merck Patent Gmbh Liquid formulation containing cetuximab
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
AU2003251592A1 (en) 2002-06-21 2004-01-06 Biogen Idec Inc. Buffered formulations for concentrating antibodies and methods of use thereof
US9415102B2 (en) 2002-09-06 2016-08-16 Alexion Pharmaceuticals, Inc. High concentration formulations of anti-C5 antibodies
AR043811A1 (en) 2003-03-31 2005-08-17 Alza Corp NON-WATERPROOF SINGLE PHASE VEHICLES AND FORMULATIONS USING THESE VEHICLES
DE10337789A1 (en) 2003-08-14 2005-09-15 3M Espe Ag Single dose syringe for a multi-component material
JO3000B1 (en) 2004-10-20 2016-09-05 Genentech Inc Antibody Formulations.
US20060141040A1 (en) 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
US20060271014A1 (en) 2005-05-31 2006-11-30 Mallinckrodt Inc. Heat retention device for a syringe and methods of use
EP1916997B1 (en) 2005-08-05 2018-04-18 Amgen Inc. Stable aqueous protein pharmaceutical formulations and their preparation
JP2009507641A (en) 2005-09-13 2009-02-26 ベイワン ウレタン システムズ， エルエルシー Dynamic spiral stirrer and stirrer using the spiral stirrer
US20070072146A1 (en) 2005-09-29 2007-03-29 Dentsply Research And Development Corp. Dispensing syringe having multiple barrels for discharging a dental composition
BRPI0620316A2 (en) 2005-12-21 2011-11-08 Wyeth Corp Low viscosity protein formulations and their uses
US8383114B2 (en) 2007-09-27 2013-02-26 Amgen Inc. Pharmaceutical formulations
PE20091174A1 (en) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd LIQUID FORMULATION WITH HIGH CONCENTRATION OF ANTIBODY CONTENT
US8197122B2 (en) 2008-04-24 2012-06-12 Tyco Healthcare Group Lp Dynamic mixing applicator
WO2010082826A1 (en) 2009-01-16 2010-07-22 Mahayana Holding B.V. Container for a liquid material to be supplied to the human or animal body which is adapted to heat the material, device for powering and method for heating such a container
GB0902354D0 (en) 2009-02-13 2009-04-01 3M Innovative Properties Co Syringes for dispensing multicomponent material
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
AR078161A1 (en) 2009-09-11 2011-10-19 Hoffmann La Roche VERY CONCENTRATED PHARMACEUTICAL FORMULATIONS OF AN ANTIBODY ANTI CD20. USE OF THE FORMULATION. TREATMENT METHOD
US20110226650A1 (en) 2009-12-21 2011-09-22 Genentech, Inc. Antibody formulation
US9033261B2 (en) 2010-01-15 2015-05-19 Xiamen Solex High-Tech Industries Co., Ltd. Single point touch shower
EP3216462A3 (en) 2010-02-26 2017-12-20 Novo Nordisk A/S Stable antibody containing compositions
US20130171128A1 (en) 2010-03-02 2013-07-04 Amgen Inc. Reducing viscosity of pharmaceutical formulations
ES2659079T3 (en) 2010-03-09 2018-03-13 Janssen Biotech, Inc. Non-aqueous suspension formulations of reduced viscosity at high concentration
US9072668B2 (en) 2010-03-09 2015-07-07 Janssen Biotech, Inc. Non-aqueous high concentration reduced viscosity suspension formulations of antibodies
US20110223208A1 (en) 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
WO2011121560A2 (en) 2010-03-31 2011-10-06 Universite De Geneve Stabilized antibody preparations and uses thereof
JP2013525484A (en) 2010-05-03 2013-06-20 ジェネンテック， インコーポレイテッド Compositions and methods useful for reducing the viscosity of protein-containing formulations
CN102946903B (en) 2010-05-14 2014-11-26 安进公司 High concentration antibody formulations
JP5980782B2 (en) 2010-07-30 2016-08-31 ファイザー・インク Protein tandem purification
AU2012240050B2 (en) 2011-04-07 2016-01-21 Glaxosmithkline Llc Formulations with reduced viscosity
US20140044727A1 (en) 2011-04-07 2014-02-13 Glaxosmithkline Llc Formulations with reduced viscosity
EP3020428A1 (en) 2011-04-21 2016-05-18 AbbVie Inc. Wearable automatic injection device for controlled administration of therapeutic agents
UA116189C2 (en) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. FORMULATION FOR ANTI-α4β7 ANTIBODY
GB201113880D0 (en) 2011-08-12 2011-09-28 Archimed Llp Novel compositions
MX352823B (en) 2011-10-28 2017-12-04 Integritybio Inc Protein formulations containing amino acids.
PE20142275A1 (en) 2012-03-07 2015-01-08 Lilly Co Eli IL-17 ANTIBODY FORMULATION
EP3427721A1 (en) 2012-05-18 2019-01-16 Genentech, Inc. High-concentration monoclonal antibody formulations
MA37777B1 (en) 2012-06-21 2017-07-31 Ucb Pharma Sa Pharmaceutical preparation
US9358350B2 (en) 2012-08-06 2016-06-07 Elwha Llc Systems and methods for wearable injection guides
FR2994390B1 (en) 2012-08-10 2014-08-15 Adocia METHOD FOR LOWERING THE VISCOSITY OF HIGH CONCENTRATION PROTEIN SOLUTIONS
FR2995214B1 (en) 2012-09-10 2014-11-21 Adocia REDUCED VISCOSITY SOLUTION OF HIGH CONCENTRATION PROTEIN
CN104768578A (en) 2012-10-25 2015-07-08 米迪缪尼有限公司 Stable, low viscosity antibody formulation
WO2014141149A1 (en) 2013-03-15 2014-09-18 Glaxosmithkline Intellectual Property (No.2) Limited Formulations with reduced viscosity
TWI679019B (en) 2013-04-29 2019-12-11 法商賽諾菲公司 Anti-il-4/anti-il-13 bispecific antibody formulations
KR102651018B1 (en) 2013-09-11 2024-03-27 이글 바이오로직스 인코퍼레이티드 Liquid protein formulations containing viscosity-lowering agents
HUE047194T2 (en) 2013-09-27 2020-04-28 Hoffmann La Roche Anti-pdl1 antibody formulations
WO2015196091A1 (en) 2014-06-20 2015-12-23 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
US20150374916A1 (en) 2014-06-27 2015-12-31 Allergan, Inc. Laterally connected syringes with integrated mixing hub and static mixer
JP2017527560A (en) 2014-09-03 2017-09-21 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ Stable anti-IL-4Ralpha antibody formulation
US20160058863A1 (en) 2014-09-03 2016-03-03 Board Of Regents, The University Of Texas System Low viscosity concentrated protein dispersions
US11471479B2 (en) 2014-10-01 2022-10-18 Eagle Biologics, Inc. Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
AU2015335743B2 (en) 2014-10-23 2020-12-24 Amgen Inc. Reducing viscosity of pharmaceutical formulations
WO2016109822A1 (en) 2014-12-31 2016-07-07 Novelmed Therapeutics, Inc. Formulation of aglycosylated therapeutic antibodies
WO2017055966A1 (en) * 2015-10-01 2017-04-06 Pfizer Inc. Low viscosity antibody compositions
CA3129181C (en) 2015-10-23 2023-10-31 Reform Biologics, Llc Excipient compounds for biopolymer formulations
US10646569B2 (en) 2017-05-16 2020-05-12 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity

Also Published As

Publication number Publication date
WO2018211517A1 (en) 2018-11-22
US11738082B2 (en) 2023-08-29
US10646569B2 (en) 2020-05-12
EP3624846A1 (en) 2020-03-25
US20180333493A1 (en) 2018-11-22
US20240115702A1 (en) 2024-04-11
US20200254094A1 (en) 2020-08-13
CA3063324A1 (en) 2018-11-22

Similar Documents

Publication Publication Date Title
SG11202003754YA (en) High concentration protein formulations with reduced viscosity
HK1253065A1 (en) Compounds targeting proteins, compositions, methods, and uses thereof
GB201502305D0 (en) Protein
GB201502306D0 (en) Protein
SG11201704010UA (en) Fibroin-derived protein composition
HK1247933A1 (en) Fusion protein containing bdnf
IL275435B (en) Tatk-cdkl5 fusion proteins, compositions, formulations, and use thereof
IL258570A (en) Stable protein compositions
GB201515745D0 (en) Proteins
GB201511787D0 (en) Proteins
HK1254980A1 (en) Blended formulations
GB201608197D0 (en) Novel proteins
IL265831A (en) Compositions and methods for protein expression and delivery
IL283229A (en) High concentration protein formulation
ZA201708173B (en) High concentration formulation
GB201513033D0 (en) Proteins
HK1257426A1 (en) Anti-factor d antibody formulations
GB2558968B (en) G Proteins
EP3180016A4 (en) Linaclotide stable composition
EP3350565A4 (en) Small sample injection vial
GB201522610D0 (en) Protein
GB201515337D0 (en) Protein Expression
GB201515744D0 (en) Proteins
GB201503778D0 (en) Proteins
GB201511478D0 (en) Blended formulations